Research & Education

IASLC European Webinar Series - 2015/2016 - Maintenance Therapy in Advanced Non-Small Cell Lung Cancer

Wednesday, February 10, 2016 - 7 p.m. CET - Recording Available
Wilfried Ernst Erich Eberhardt, MD

Wilfried Ernst Erich Eberhardt, MD
Senior Staff Member,
Department of Medical Oncology,
West German Cancer Center,
Ruhrlandklinik,
University Hospital Essen,
University Duisburg-Essen

Name of Reviewer(s): 

              

Fred Hirsch, MD, PhD –Speakers Bureau/Advisory Board: Astrazeneca, Genentech, BMS, Lilly and Abbvie.

Name of Planner(s): 

 

  Deb Whippen-Nothing to Disclose

Name of Activity: 

 

Maintenance Therapy in Advanced Non-Small Cell Lung Cancer

Date of Activity:

 

February 10, 2016

Faculty/Speaker(s):

Financial DISCLOSURES

COI Resolution: Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.

 

Wilfried Ernst Erich Eberhardt, MD Advisory Board: Astra Zeneca, Roche, Eli Lilly, Novartis, Pfizer, Bayer, Sanofiaventis, Boehringer-Ingelheim, Bristol-Meyers Squibb, GSK, Amgen, Teva, Astellas, Merck.

Honoraria: Pierre Fabre, Merck, Astra Zeneca, Roche, Eli Lilly, Novartis, Pfizer, Bayer, Sanofiaventis, OSI, Bristoll-Meyers Squibb, GSK, Boehringer-Ingelheim, Daichi, Sankyo, Amgen.

Research Finding: Eli Lilly

Type of Activity: 

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?

                         No

If yes, please list:

 

In patients with metastasized non-small-cell lung cancer (NSCLC), the current typical first-line treatment approaches are four cycles of cisplatin and pemetrexed in patients with non-squamous cell carcinoma. As an alternative, centers still administer carboplatin, paclitaxel and bevacizumab and these are given for four to six cycles. Strategies of maintenance chemotherapy include "switch maintenance" with changing from four cycles carbo/pacli/bev or other non-pemetrexed combinations to maintenance pemetrexed until the time of progression and "continuation maintenance" with keeping single agent pemetrexed as ongoing treatment following four cycles of cisplatin and pemetrexed. Both strategies have been shown in large prospectively randomized phase-III trials (JMEN, PARAMOUNT) to significantly improve median overall survival at about three months as well as double the median PFS at very little costs of toxicity. This strategy has since become an important option to patients for the management armamentatium of metastasized non-small-cell lung cancer without any druggable driver mutation.

In this webinar, we will:

  • Discuss these large randomized phase-III trials and their implications.
  • Evaluate long-term toxicities described under prolonged maintenance chemotherapy with pemetrexed in these patients.
  • Discuss the administration of maintenance bevacizumab following initial treatment with carboplatin/paclitaxel and bevacizumab.
  • Implement the use of EGFR TKI as maintenance treatment in patients with a) proven EGFR mutation, and b) at least stable disease results from induction chemotherapy with unknown/unavailable EGF-mutation status.

We will conclude our discussion with a description of the current situation in the treatment of squamous cell carcinoma. Maintenence chemotherapy or maintenance therapy options will probably be reevaluated with now available active immunotherapy drugs in specific treatment situations. We will give a short overview of ongoing clinical studies open to participation for these important clinical issues.

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

 

CME INFORMATION:

Financial/Commercial Relationships DISCLOSURES

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. 

 This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/moderators/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE

In patients with metastasized non-small-cell lung cancer (NSCLC), the current typical first-line treatment approaches are four cycles of cisplatin and pemetrexed in patients with non-squamous cell carcinoma. As an alternative, centers still administer carboplatin, paclitaxel and bevacizumab and these are given for four to six cycles. Strategies of maintenance chemotherapy include "switch maintenance" with changing from four cycles carbo/pacli/bev or other non-pemetrexed combinations to maintenance pemetrexed until the time of progression and "continuation maintenance" with keeping single agent pemetrexed as ongoing treatment following four cycles of cisplatin and pemetrexed. Both strategies have been shown in large prospectively randomized phase-III trials (JMEN, PARAMOUNT) to significantly improve median overall survival at about three months as well as double the median PFS at very little costs of toxicity. This strategy has since become an important option to patients for the management armamentatium of metastasized non-small-cell lung cancer without any druggable driver mutation.

TARGET AUDIENCE

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

DISCLAMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Thank you for your participation.

DOWNLOAD RECORDING

 

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program. CME credit is only available to attendees of the live webinar.

Location Local time Time zone UTC offset
New York (U.S.A. - New York) Wednesday, February 10, 2016 at 1:00:00 PM EST UTC-5 hours
Berlin (Germany) Wednesday, February 10, 2016 at 7:00:00 PM CET UTC+1 hour
Amsterdam (Netherlands) Wednesday, February 10, 2016 at 7:00:00 PM  CET UTC+1 hour
Paris (France) Wednesday, February 10, 2016 at 7:00:00 PM CET UTC+1 hour
Geneva (Switzerland) Wednesday, February 10, 2016 at 7:00:00 PM CET UTC+1 hour
London (United Kingdom) Wednesday, February 10, 2016 at 6:00:00 PM GMT UTC
Barcelona (Spain) Wednesday, February 10, 2016 at 7:00:00 PM CET UTC+1 hour
Prague (Czech Republic) Wednesday, February 10, 2016 at 7:00:00 PM CET UTC+1 hour
Moscow (Russia) Wednesday, February 10, 2016 at 9:00:00 PM MSK UTC+3 hours
Dublin (Ireland) Wednesday, February 10, 2016 at 6:00:00 PM GMT UTC
Rome (Italy) Wednesday, February 10, 2016 at 7:00:00 PM CET UTC+1 hour
Vienna (Austria) Wednesday, February 10, 2016 at 7:00:00 PM CET UTC+1 hour
Corresponding UTC (GMT) Wednesday, February 10, 2016 at 6:00:00 PM     

How to use the Time Zone Converter